Media stories about Abeona Therapeutics (NASDAQ:ABEO) have been trending somewhat positive on Wednesday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Abeona Therapeutics earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.5314892446143 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news articles that may have effected Accern Sentiment’s rankings:

A number of equities analysts have weighed in on the company. Maxim Group set a $14.00 price target on Abeona Therapeutics and gave the stock a “buy” rating in a research report on Saturday, May 13th. Zacks Investment Research downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $21.00 price target on shares of Abeona Therapeutics in a research report on Tuesday, June 6th. BidaskClub downgraded Abeona Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Abeona Therapeutics in a research report on Thursday, June 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $17.86.

Abeona Therapeutics (NASDAQ ABEO) traded down 6.514% during midday trading on Wednesday, hitting $13.275. The stock had a trading volume of 732,159 shares. The stock’s 50-day moving average is $9.13 and its 200-day moving average is $6.54. The stock’s market capitalization is $534.81 million. Abeona Therapeutics has a 1-year low of $4.05 and a 1-year high of $15.25.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.07. Abeona Therapeutics had a negative return on equity of 26.66% and a negative net margin of 2,746.38%. The company had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.21 million. On average, equities research analysts anticipate that Abeona Therapeutics will post ($0.67) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Abeona Therapeutics (ABEO) Share Price” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/09/06/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-abeona-therapeutics-abeo-share-price.html.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Insider Buying and Selling by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Stock Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related stocks with our FREE daily email newsletter.